The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.

Dejan  Juric

Stock and Other Ownership Interests  - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics

Consulting or Advisory Role - Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; Petra Pharma; PIC Therapeutics; Relay Therapeutics; Silverback Therapeutics; Syros Pharmaceuticals; Vibliome Therapeutics

Research Funding - Amgen (Inst); Eisai (Inst); EMD Serono (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Placon (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)

Hope S.  Rugo

Honoraria - Mylan; Puma Biotechnology; Samsung Bioepis

Consulting or Advisory Role - Napo Pharmaceuticals

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)

Stephen K.L.  Chia

Honoraria - AstraZeneca; Exact Sciences; Lilly; Merck; Novartis; Pfizer; Roche

Consulting or Advisory Role - Novartis; Roche

Research Funding - AstraZeneca (Inst); Genentech (Inst); Genomic Health (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)

Florence  Lerebours

Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Seagen

Travel, Accommodations, Expenses - Eisai; Mundipharma; Novartis; Pfizer; Roche

Manuel  Ruiz-Borrego

Consulting or Advisory Role - Novartis; Pfizer; Pierre Fabre

Speakers' Bureau - AstraZeneca; Novartis; Pfizer

Pamela  Drullinsky

Research Funding - Novartis (Inst)

Eva M.  Ciruelos

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche

Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Roche

Travel, Accommodations, Expenses - Pfizer; Roche

Patrick  Neven

Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)

Yeon Hee  Park

Honoraria - Merck; Novartis; Pfizer

Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche

Research Funding - AstraZeneca; Gencurix (Inst); Novartis; Pfizer; Roche (Inst)

Christina H.  Arce

Employment - Novartis

Stock and Other Ownership Interests  - Novartis

Ennan  Gu

Employment - Novartis Institutes for BioMedical Research

Stock and Other Ownership Interests  - Novartis Institutes for BioMedical Research

Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research

Mukta  Joshi

Employment - Novartis

Stock and Other Ownership Interests  - Novartis

Estelle  Roux

Employment - Novartis

Murat  Akdere

Employment - Biogen (I); Novartis; Sanofi (I)

Stock and Other Ownership Interests  - Biomarin (I); Novartis

Travel, Accommodations, Expenses - Biogen (I); Novartis; Sanofi (I)

Nicholas C.  Turner

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Zeno pharmaceuticals

Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)